Companies → Asymchem Laboratories (Tianjin) Co., Ltd.
Save to list
Remove

Asymchem Laboratories (Tianjin) Co., Ltd.

China, Tianjin
Description
by AI
Founded in 1997 and located in the Tianjin Economic and Technological Development Zone, Asymchem is one of the world's leading providers of pharmaceutical and biotechnology services including Contract Research, Development and Manufacturing (CRDMO) service to multinational pharmaceutical companies, biotechnology companies, and a diversity of global generic companies. Since its founding, Asymchem has fully integrated global resources, established branches and wholly-owned subsidiaries in the United States, Japan, Switzerland, the Netherlands, and China, forming a global operating platform. Through its headquarters, six R&D centers and eight GMP production bases around the world, Asymchem provides broad and integrated pharmaceutical R&D and manufacturing services covering APIs, advanced intermediates, biologics and cGMP manufacturing of sterile injectable, oral solids and sustained-release formulations. Comprehensive scale and growth, vertical integration, leading technology platforms, global presence and world-class leadership combine to secure Asymchem's position at the forefront of pharmaceutical outsourcing as it actively supports the global pharmaceutical industry in R&D and manufacturing to provide high-quality and affordable medicines to all.
Address:

No.6

Dongting 3rd Street

Economic Technology Development Zone Tianjin

Tianjin

300000 China

Website:
Revenue
FRA - Delayed Quote - EUR
7K90.F
8.05 -0.05 (-0.62%)
At close March 20 15:30 UTC
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/21/2026
Market Cap: 4.20 B
Enterprise Value: 3.29 B
Trailing P/E: 22.49
Forward P/E: N/A
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 3.71
Price/Book (mrq): 1.34
Enterprise Value/Revenue: 4.17
Enterprise Value/EBITDA: 21.22
Financial Highlights
Profitability and Income Statement
Profit Margin: 16.51%
Return on Assets (ttm): 2.71%
Return on Equity (ttm): 6.05%
Revenue (ttm): 6.29 B
Net Income Avi to Common (ttm): 1.04 B
Diluted EPS (ttm): 0.36
Balance Sheet and Cash Flow
Total Cash (mrq): 7.88 B
Total Debt/Equity (mrq): 1.84%
Levered Free Cash Flow (ttm): 123.24 M
Company is likely to buy
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.